Sunshine Biopharma (SBFM)
NASDAQ:SBFM
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$0.95 - $2.43
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$4.90M
Enterprise Value-$3.41M
Total Cash (Recent Filing)$9.12M
Total Debt (Recent Filing)$812.42K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding4,905,945
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-0.70
Enterprise Value/Revenue-0.09
Enterprise Value/Gross Profit-0.28
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$50.00M
Bulls Say, Bears Say
Bulls Say
Reasonable Gross MarginsSustained gross margins near 31–39% indicate the core product economics are viable for a generics specialist. Durable unit economics provide a runway to reach profitability if operating expenses are controlled and scale continues, supporting margin sustainability over a multi‑quarter horizon.
Low Leverage / Zero Reported DebtMinimal reported debt and modest historical leverage reduce refinancing and solvency risk, preserving financial flexibility. A low‑debt profile supports continued investment in commercialization or R&D and lowers bankruptcy risk while the company works to stabilize cash flows.
Asset‑light Generics Commercialization ModelRelying on third‑party manufacturers and acquiring commercial rights enables scalable, lower‑capex growth. This asset‑light model lets management expand the generic portfolio and enter markets faster, preserving capital and improving return potential as revenues scale.
Bears Say
Persistent Negative Cash FlowConsecutive annual operating and free cash flow deficits create structural cash burn that increases reliance on external financing. Over months this erodes runway, forces dilutive raises or expensive financing, and constrains the firm's ability to invest in commercialization or R&D without clear path to self‑funding.
Ongoing Operating LossesDespite revenue scale, persistent negative operating and net margins show the company has not converted gross profits into sustainable earnings. This structural profitability gap suggests either elevated fixed/SG&A costs or pricing pressures in generics that must be resolved to achieve durable profitability.
Concentrated Shareholder Control / Governance RiskHigh insider voting control and a board mandate for a potential reverse split signal concentrated decision‑making. Over the medium term this can lead to governance risks, limit minority shareholder protections, and enable structural actions (capital structure changes) that may not align with all stakeholders' interests.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $0.95 and its highest was $2.43 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $4.90M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is May 13, 2026 which is in 29 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -0.16.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 4,905,945 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug discovery and development, particularly in the areas of oncology and related treatments. Sunshine Biopharma's core products include a pipeline of drug candidates that address unmet medical needs, leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---